

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Multiple Technology Appraisal (MTA)

Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events
(review of Technology Appraisal No. 90)

Response to consultee and commentator comments on the provisional matrix of consultees and commentators

Version of matrix of consultees and commentators reviewed:				
Provisional matrix of consultees and commentators sent for consultation				
Summary of comments, action taken, and justification of action:				
	<i>Proposal:</i>	<i>Proposal made by:</i>	<i>Action taken:</i> Removed/Added/Not included/Noted	<i>Justification</i>
1.	It would be appropriate to consider inviting manufacturers of generic versions of clopidogrel to comment e.g. Teva Pharmaceuticals	<i>British Cardiovascular Society</i>	<i>Not added</i>	<i>Not currently licensed</i>

